

1 **Large-scale Analysis of 2,152 dataset reveals** 2 **key features of B cell biology and the** 3 **antibody repertoire**

4 Xiuja Yang^{1,2,a*}, Minhui Wang^{1,b*}, Dianchun Shi^{3*}, Yanfang Zhang^{2,c*}, Huikun Zeng^{1,2*}, Yan Zhu^{2*},
5 Chunhong Lan^{1,2,d*}, Jiaqi Wu², Yang Deng⁴, Shixin Guo⁵, Lijun Xu⁶, Cuiyu Ma^{1,2}, Yanxia Zhang²,
6 Rongrong Wu³, Jinxia Ou^{7,e}, Chu-jun Liu⁸, Changqing Chang⁹, Wei Yang^{10,f}, Huijie Zhang¹¹, Jun
7 Chen¹², Lijie Qin⁶, Hongwei Zhou^{7,g}, Jin-Xin Bei⁸, Lai Wei⁵, Guangwen Cao^{4†}, Xueqing Yu^{3†},
8 Zhenhai Zhang^{1,2,13,14,h†}

9 ¹State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney
10 Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou,
11 510515, China

12 ²Department of Bioinformatics, School of Basic Medical Sciences, Southern Medical University,
13 Guangzhou 510515, China

14 ³Department of Geriatrics, Guangzhou First People's Hospital, School of Medicine, South China
15 University of Technology, Guangzhou 510030, China

16 ⁴ Department of Epidemiology, Second Military Medical University, 800 Xiangyin Rd., Shanghai
17 200433, China

18 ⁵State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University,
19 Guangzhou 510060, China

20 ⁶Department of Emergency, Henan Provincial People's Hospital, Zhengzhou 450003, China

21 ⁷Microbiome Medicine Center, Division of Laboratory Medicine, Zhujiang Hospital, Southern
22 Medical University, Guangzhou 510282, China

23 ⁸Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China,
24 Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University, Guangzhou 510030,
25 China

26 ⁹Integrate Microbiology Research Center, South China Agricultural University, Guangzhou, 510642,
27 China

28 ¹⁰Department of Pathology, School of Basic Medical Sciences, Southern Medical University,
29 Guangzhou, 510515, China

30 ¹¹Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University,
31 Guangzhou 510515, China

32 ¹²MOE Laboratory of Biosystems Homeostasis & Protection and Innovation Center for Cell Signaling
33 Network, College of Life Sciences, Zhejiang University, Hangzhou 310058, China

34 ¹³Center for precision medicine, Guangzhou First People's Hospital, School of Medicine, South China
35 University of Technology, Guangzhou 510030, China

36 ¹⁴Key Laboratory of Mental Health of the Ministry of Education, Guangdong-Hong Kong-Macao
37 Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Southern Medical
38 University, Guangzhou 510515, China

39 *These authors contributed equally to this work.

40 †To whom correspondence should be addressed:

41 Zhenhai Zhang, zhenhaismu@163.com

42 Xueqing Yu, yuxueqing@gdph.org.cn

43 Guangwen Cao, gcao@smmu.edu.cn

44

45

46 ORCID:

47 ^a0000-0003-4036-4995

^b0000-0001-8121-7786

48 ^c0000-0001-9309-7347

49 ^d0000-0001-5030-8247

^e0000-0002-1680-2425

50 ^f0000-0001-9438-7215

51 ^g0000-0003-2472-8541

^h0000-0002-4310-0525

52

53 *Running title: Key features of antibody repertoire.*

54 Abstract

55 Antibody repertoire sequencing (Ig-seq) has been widely used in studying humoral responses, with
56 promising results. However, the promise of Ig-seq has not yet been fully realized, and key features of
57 the antibody repertoire remain elusive or controversial. To clarify these key features, we analyzed
58 2,152 high-quality heavy chain antibody repertoires, representing 582 donors and a total of 360
59 million clones. Our study revealed that individuals exhibit very similar gene usage patterns for
60 germline V, D, and J genes and that 53 core V genes contribute to more than 99% of the heavy chain
61 repertoire. We further found that genetic background is sufficient but not necessary to determine usage
62 of V, D, and J genes. Although gene usage pattern is not affected by age, we observed a significant
63 sex preference for 24 V genes, 9 D genes and 5 J genes, but found no positional bias for V-D and D-J
64 recombination. In addition, we found that the number of observed clones that were shared between
65 any two repertoires followed a linear model and noted that the mutability of hot/cold spots and single
66 nucleotides within antibody genes suggested a strand-specific somatic hypermutation mechanism.
67 This population-level analysis resolves some critical characteristics of the antibody repertoire and thus
68 may serve as a reference for research aiming to unravel B cell-related biology or diseases. The metrics
69 revealed here will be of significant value to the large cadre of scientists who study the antibody
70 repertoire.

71 **Keywords:** B-cell biology, antibody repertoire, large-scale analysis, high-throughput sequencing,
72 Ig-seq

73

74

75

76

77 **Introduction**

78 The antibody repertoire is defined as the entire collection of B-cell receptors and antibodies that
79 grant protection against a plethora of pathogens. A deeper understanding of the antibody repertoire
80 under normal physiological conditions and in pathogenic conditions may shed light on functional
81 immune responses and reveal the full scope of their protective and pathogenic functions. However,
82 despite this great potential, collecting enough antibody molecules to capture the immense diversity of
83 the antibody repertoire has been a critical challenge.

84 Using high-throughput sequencing technology, Weinstein et al. developed antibody repertoire
85 sequencing (Ig-seq) (Weinstein et al., 2009), which allows researchers to capture millions or even
86 billions of antibody variable regions within a single experiment. The vast amount of data acquired by
87 Ig-seq enables a deeper and more thorough evaluation of the key features of the antibody repertoire, as
88 well as its constituent antibody molecules, at the single-nucleotide level. In the past decade, Ig-seq has
89 advanced the study of many important sub-fields of B-cell immunology, such as antibody discovery
90 (Reddy et al., 2010; Zhu et al., 2013a), vaccination development (Jackson et al., 2014; Jiang et al.,
91 2013; Joyce et al., 2016; Li et al., 2012), infection (Krebs et al., 2019; Parameswaran et al., 2013; Wu
92 et al., 2015; Wu et al., 2011a), allergy (Hoh et al., 2016; Patil et al., 2015; Wu et al., 2014),
93 autoimmune disease (Stern et al., 2014; Tipton et al., 2015; von Büdingen et al., 2012), and cancer
94 immunology (Faham et al., 2012; Gawad et al., 2012; Kurtz et al., 2015). For example, using Ig-seq
95 coupled with single-cell cloning technology, we and others identified thousands of HIV-1-neutralizing
96 antibodies that bind to different epitopes and delineated their lineage-dependent maturation pathways
97 (Bonsignori et al., 2016; Wu et al., 2015; Wu et al., 2011b; Zhu et al., 2013b). Studies of antibody
98 repertoires after virus infection also led to the discovery of antibody convergence – a mechanism
99 whereby identical or very similar antibody clonotypes are generated in different individuals facing the
100 same selective pressure (Parameswaran et al., 2013). These results suggested that the antibody

101 repertoire could be used to track an individual's immune history as well as to monitor the
102 immunological memory of a community.

103 The use of antibody repertoire in autoimmune diseases has provided important insight into both
104 disease mechanisms and fundamental B cell biology. For example, Tipton et al. revealed that systemic
105 lupus erythematosus (SLE) autoreactivity occurred during a polyclonal activation of
106 IGHV4-34-dominant B cell clones via both germinal center-dependent and germinal
107 center-independent mechanisms (Tipton et al., 2015). Büdingen et al. discovered that a pool of clonal
108 related antibodies participates in a robust bidirectional exchange across the blood-brain barrier (von
109 Büdingen et al., 2012). Analyzing the antibody repertoires of patients with the same disease, Stern et
110 al. found that majority of the disease-related autoantibodies matured outside of the central nervous
111 system and trafficked freely across tissue barriers (Stern et al., 2014).

112 Prior studies using Ig-Seq accumulated a wealth of antibody repertoire data. This under-explored
113 population-level big data could potentially help us resolve the important yet unclear or controversial
114 features of the B cell biology and the antibody repertoire. For instance, what are the germline V, D,
115 and J gene usage patterns and how similar are they between individuals? What are the factors
116 determining these patterns if they do exist? Is there preferential recombination between V-D and D-J
117 genes? What are the rules that govern the somatic hypermutations (SHM)? What are the proportion of
118 public clones between individuals and what functions do these clones exert?

119 With these unsolved or controversial questions in mind, we collected 2,152 high quality antibody
120 heavy chain repertoires and performed thorough and in-depth analyses. These analyses revealed
121 patterns of B cell biology as well as key features of the antibody repertoire, which will be of
122 significant value to the large cadre of scientists in the field.

123

124 Results

125 Overview of datasets used in this study

126 The immense diversity of B cells is derived from two important biological processes: germline
127 gene segment recombination, which introduces indels in complementarity-determining region 3, and
128 activation-induced cytidine deaminase, which leads to somatic hypermutations in the antibody
129 variable regions during affinity maturation. Thus, any mutation or indel in the variable region may be
130 important for understanding and revealing B cell biology. It is thus essential to understand the
131 sequencing errors that are intrinsic to Ig-seq approaches. For example, 454 sequencing often generates
132 indels in the homopolymer region, and PCR amplification and high-throughput sequencing can also
133 generate base errors and chimeras. These intrinsic errors would be easily mistaken as somatic
134 hypermutation (SHM) generated during affinity maturations. We therefore only included samples that
135 were sequenced by Illumina instruments. We also required the sequencing reads to cover a minimum
136 of 500 bp, the primers to capture the full spectrum of antibodies generated by any V(D)J
137 recombination, and a minimum number of productive reads ([Materials and Methods](#)). After filtering
138 on these stringent criteria, we identified a total of 1,857 repertoires from 33 published studies and 295
139 repertoires from in-house sequencing for further analysis ([Figure 1a](#)).

140 The sample-associated metadata, including age, sex, physiological condition, tissue origin, and
141 amplification method, are shown in [Figures 1b-f](#). Age composition was more balanced for the sampled
142 individuals than for the samples ([Figure 1b and Figure S1](#)), and the number of individuals for each age
143 group is more than 30 (more than 80 samples for each age group). Slightly more than half of the
144 samples were from females ([Figure 1c](#)). Sequencing libraries for all recruited samples were mainly
145 amplified using multiplex PCR ([Figure 1d](#)). Donor conditions and the sources of the samples were
146 classified into 13 and 6 directories respectively ([Figures 1e and 1f](#)). These repertoires covered a broad
147 spectrum of diseases, such as autoimmune disease, cancer, virus infection, and more. The majority

148 (76.8%) of samples were derived from peripheral blood mononuclear cells (PBMCs); there were also
149 samples from bone marrow, intestine, lung, and spleen. Overall, we included a total of 7,378,354,271
150 raw reads in our analysis.

151 **The core V gene set determines the clear majority of antibodies**

152 The variable usage of germline genes represents the first level of antibody repertoire diversity
153 and is believed to affect immune function (Glanville et al., 2011). Naïve germline gene usage may be
154 optimized for interactions with common antigens and may serve as a control to detect
155 pathology-driven repertoire variation in the B cell memory compartment (Laserson et al., 2014). For
156 these reasons, the gene usage pattern has been studied at a small scale and under different
157 experimental settings using two different quantification methods: gene usage and gene expression.
158 Gene usage quantifies genes at the level of individual clones, whereas gene expression quantifies the
159 occurrence of genes with each read. Gene expression is sensitive to cell type composition, such as
160 clonal expansion in response to an adaptive immune stimulus, and thus is less optimal for comparisons
161 between samples with differences in source tissues, immune status, and donor health.

162 Library preparation technique also affects the quantification of genes. Two amplification
163 strategies were used in the high-quality Ig-seq datasets: multiplex polymerase chain reaction (MPCR)
164 and rapid amplification of cDNA ends (RACE). Previous studies showed that MPCR can introduce
165 bias in library sequencing, even with an optimized primer set, while RACE introduces less bias (He et
166 al., 2015; Liu et al., 2016; Robins, 2013). We compared quantitative metrics for 1,409 and 743
167 samples amplified by MPCR and RACE, respectively. D and J gene usage were less influenced by
168 either RACE or MPCR. However, V gene usage was more consistent between RACE and MPCR
169 ([Figure S2a-f and Materials and Methods](#)) due to the various primers on the 5' ends. We therefore
170 selected gene usage for the following analyses unless otherwise specified.

171 It has been long known that V(D)J gene segments are preferentially used or expressed, and the
172 idea of a core gene set has been proposed (Boyd et al., 2010). However, which genes are in the core
173 set and the extent to which they contribute to the antibody repertoire remains unclear. Taking

174 advantage of the large data set used in this study, we plotted the gene usage of V, D, and J genes. As
175 shown in [Figure 2](#), although the number of V genes present in each sample varies from 15
176 (SRR3620039) to 99 (SRR8365259 and SRR4417619) along with the sequencing depth, we observed
177 preferential usage of V genes. For example, IGHV3-30 and IGHV3-23 were present in all samples,
178 while IGHV3-30-52 only appeared in one sample (SRR4417619). Accounting for both the prevalence
179 of specific genes and their contribution to the antibody repertoire, we identified a core set of 53 V
180 genes ([Figures 2b and 2c](#), [Materials and Methods](#)). To our surprise, there are 3 pseudogenes,
181 IGHV3-11 (2,147 samples, 581 donors), IGHV3-69-1 (2,128 samples, 579 donors), and IGHV3-71
182 (1,691 samples, 464 donors), in the core gene set. All core V genes contribute to a median of 99.33%
183 of clones ([Figure S3](#)). The remaining V genes thus either contribute little to the repertoire or are not
184 present. IGHJ3, IGHJ4, and IGHJ5 are present in all samples, while IGHJ1, IGHJ2, and IGHJ6 occur
185 in 2,149, 2,150, and 2,151 samples, respectively. Of these, IGHJ4 and IGHJ6 are found in a median of
186 50.56% and 18.37% clones. IGHJ1 is the least used gene, contributing to a median of 2.15% clones.
187 Three D genes, IGHD3-10, IGHD3-22, and IGHD6-19, are more prevalent. Statistics for V, D, and J
188 gene segments are shown in [Table S1](#), sorted by their occurrence in 582 individuals.

189 **Genetic background is sufficient but not necessary for achieving consistent germline** 190 **gene usage patterns**

191 The factors that determine V gene usage patterns have been of great interest in the field, with
192 different studies yielding different results. By comparing the repertoires of monozygotic twins and
193 unrelated individuals, Glanville et al. concluded that gene usage patterns are heritable, whereas
194 Arnaout et al., Briney et al., and Laserson et al. reported that an individual's gene usage pattern is
195 almost identical or remarkably consistent among individuals (Briney et al., 2012; Glanville et al., 2011;
196 Laserson et al., 2014). Thus, the effect of genetic background on V gene usage pattern is still unclear.

197 We therefore selected 109 repertoires, all amplified using 5'RACE, from 23 unrelated males and
198 3 pairs of monozygotic twins. From these repertoires, we calculated Pearson's correlation coefficients

199 (Pearson's r values) for pairwise V gene usage (sample pairs from the same donor were excluded). As
200 shown in [Figure 3a](#), the overall coefficients of all 104 genes are higher than 53 core genes. Further
201 scrutinizing the data revealed that most of the non-core genes had values of 0 ([Figure S4a and S4b](#)).
202 For the male-derived samples, the minimum and maximum number of uncaptured core genes are 0
203 and 13, respectively, with a median of 1 and a mean of 1.53. For the non-core gene set, the minimum
204 number is 5, with a maximum of 47, a median of 21, and a mean of 23.12. For the female-derived
205 samples, the minimum and maximum number of uncaptured core genes were 0 and 12, respectively,
206 with a median of 1 and a mean of 1.10. For the non-core gene set, the minimum number is 5, with a
207 maximum of 43, a median of 21, and a mean of 22.10. These values elevated the pairwise coefficients.
208 Therefore, we decided to use the 53 core V genes identified earlier ([Figures 2b and 2c](#)) for further
209 analyses. The Pearson's r values of unrelated donors ranged from 0.3681 to 0.9517, while those of
210 monozygotic twins of the same cell type ranged from 0.9130 to 0.9952. The higher coefficient
211 observed in monozygotic twins indicates that genetic background is sufficient to account for
212 consistent V gene usage. However, we also observed 16 unrelated sample pairs that showed a
213 coefficient higher than 0.9130, the minimum coefficient observed between monozygotic twins with
214 the same cell type. Thus, a shared genetic background is not necessary for generating repertoires with
215 very similar V gene usage. The usage patterns of D and J genes also showed the same phenomena
216 ([Figure S5a and S5b](#)), and results were similar in the female-derived samples ([Figure S5c-e](#)). We
217 therefore conclude that genetic background plays a critical role in defining antibody repertoire by
218 influencing germline gene usage. However, individuals with different genetic backgrounds can also
219 achieve a remarkably similar repertoire.

220 **V, D, and J gene usage shows sex and isotype preferences**

221 After defining the relationship between gene usage and genetic background, we went on to
222 analyze two other major factors: age and sex. Consistent with a previous study (Wang et al., 2014),
223 our results showed that there is no linear relationship between gene usage and age, regardless of sex
224 ([Figures 3b and Figure S6a-f](#)). To rigorously examine the impact of sex differences on antibody

225 repertoire gene usage, we calculated pairwise germline gene usage patterns for 499 healthy PBMC
226 samples amplified with RACE from 94 male and 164 female individuals. To our surprise, we observed
227 that 24 core V genes (Figure 3c), 5 J genes (Figure 3d), and 9 D genes (Figure 3e) showed significant
228 differences between male- and female-derived samples ($p < 0.05$, P values are listed in Table S2).

229 Previous studies reported that patients with influenza and SLE had characteristic changes in
230 antibody gene usage (Pugh-Bernard et al., 2001; Sui et al., 2009). We therefore used healthy donors as
231 background and investigated gene usage in individuals with different diseases (Figure S7a-f and Table
232 S3). For the female-derived samples, 12 V and 8 D genes were out of the range defined by 283 healthy
233 samples. We found that IGHV4-38-2 (SRR4026039 and SRR4026040) and IGHV3-23D
234 (SRR4026032, SRR4026025, and SRR4026031) had increased usage in 1 and 2 out of 6 female
235 Myasthenia Gravis patients. IGHD4-17 (SRR4026038 and SRR7230358), and IGHD3-3
236 (SRR4026022 and SRR4026031) were upregulated in 2 out of 6 female Myasthenia Gravis patients.
237 For the male-derived samples, 19 V, 7 D, and 3 J genes had either higher or lower usage compared to
238 216 healthy male samples. For example, IGHV1-18 (H7N9_00004 and H7N9_00009) and IGHV3-73
239 (H7N9_00011 and H7N9_00005) showed higher usage in 2 out of 4 H7N9-infected samples. Thus, a
240 statistical analysis of large data sets may be a powerful tool in studying the antibody repertoires of
241 unhealthy individuals.

242 We also examined gene usage in different antibody isotypes, namely IgA, IgD, IgG, and IgM.
243 There were total 51 repertoires from 5 females (14 samples) and 12 males (37 samples) available for
244 this analysis (Figure S8). IgA and IgG were clustered together, while IgD and IgM gathered in the
245 same subtree within the same donor. This is true for male (Figure S9a-c) and female (Figure S10a-c)
246 samples and is consistent with a previous study (Laserson et al., 2014).

247 **DJ recombination shows no positional bias**

248 During the recombination process, exonuclease trimming and the random addition of nucleotides
249 between VD and DJ segments create diverse junctions to account for a substantial amount of antigens
250 that may be encountered (Early et al., 1980; Tonegawa, 1983). These junctions, together with the D

251 genes, are known as complementarity-determining region 3 (CDR3), which largely determines the
252 binding specificity of an antibody (Chothia et al., 1989). Due to the functional importance of CDR3,
253 there have been extensive studies looking at VDJ recombination preferences and indels in the
254 junctions (Hansen et al., 2015; Hong et al., 2018; Saada et al., 2007; Souto-Carneiro et al., 2005;
255 Truck et al., 2015).

256 For the recombination bias studies, D and J gene segments were first classified as 5D, 3D, 5J, or
257 3J based on their position on the chromosome. The 5D and 5J categories include the D and J segments
258 located in the upstream region of their respective cluster. The 3D and 3J categories include the
259 downstream D and J gene segments. Thus, 3D and 5J segments are proximal, and 5D and 3J segments
260 are distal (Hong et al., 2018; Saada et al., 2007; Souto-Carneiro et al., 2005; Truck et al., 2015).
261 Comparing DJ recombination between neonates and adults, Souto et al. found that 3D segments
262 preferentially coupled to 5J segments (a proximal bias) throughout development, while 5D segments
263 showed biased recombination to 3J segments (a distal bias) in full-term neonates rearrangements
264 (Souto-Carneiro et al., 2005). Kidd et al. also observed a clear recombinational preference of 5D to 3J
265 and 3D to 5J segments (Kidd et al., 2016). We thus plotted VD and DJ recombination (Figure 4a)
266 using a total of 352 million productive clones that have D genes assigned (Figure 4b). Surprisingly,
267 apart from the preferential usage of core V genes, IGHJ4, IGHJ6, and a few IGHD genes, we did not
268 observe either proximal DJ or distal DJ recombination biases in our data. However, the datasets from
269 previous neonate donors did not meet our inclusion criteria, so we cannot evaluate the positional bias
270 of DJ recombination during neonatal development.

271 **D-D fusion exhibits isotype and distance preferences**

272 D-D fusion, the incorporation of multiple diversity (D) genes during heavy chain recombination,
273 contributes markedly to antibody repertoire diversity and has been thought to generate long CDR3
274 loops that frequently associate in self-reactive and polyreactive antibodies (Briney et al., 2012;
275 Larimore et al., 2012). Briney et al. reported the first quantification of V(DD)J recombinants in naïve,
276 memory IgM and IgG B cells from peripheral blood using Roche 454 sequencing of 4 healthy donors

277 (Briney et al., 2012). Using stringent criteria, they found no antibodies with D-D fusion in the memory
278 IgG population. They also reported that D gene order in cases of D-D fusion matches the order of their
279 loci in the genome.

280 In bulky antibody repertoire sequencing, it is common practice to use different 3' primers
281 targeting different isotypes. We therefore went on to explore D-D fusion in different repertoires as
282 well as different isotypes using IgScout (Safonova and Pevzner, 2019). We first examined CDR3
283 length. Total CDR3s displayed a normal distribution with a peak length of 48 nucleotides. However,
284 the lengths of CDR3s with D-D fusions were much longer, with a peak length of 66 nucleotides
285 (Figure 4b). Hence, D-D fusion does result in longer CDR3s.

286 To explore how often D-D fusion recombinants present in different antibody isotypes, we chose
287 repertoires with at least 5,000 C gene assigned clones for corresponding isotype and calculated the
288 frequency of D-D fusions. IgD had the highest D-D fusion frequency of 0.260% (median, n=104),
289 followed by 0.216% of IgM (median, n=594). IgG (median, n=489) and IgA (n=163) exhibited much
290 lower D-D fusion frequencies of 0.089% and 0.060% (median value), respectively (Figures 4c and
291 Table S4). We did not calculate the D-D fusion frequencies for IgE because too few repertoires were
292 available. These results are consistent with previous findings that D-D fusion recombinants may be
293 negatively selected during isotype switching (Souto-Carneiro et al., 2005).

294 In contrast with previous findings, however, gene order in D-D fusion did not match the order of
295 the corresponding loci in the genome (Figure 4d). The upstream D gene is defined as the "first" D
296 gene (D1) in the fused recombinants and the downstream D genes could be the "second" D gene (D2).
297 In other word, the first D gene (D1) located more 5' in the genome prefer to be the second D gene (D2)
298 in a D-D fusion event. However, D1 gene seem to prefer to fuse with downstream D genes with a span
299 of 7 (The span of adjacent D gene is 1) (Figure 4e). Surprisingly, we did not observe a positive
300 correlation between D-D fusion and D gene usage (Briney et al., 2012). The most abundant pairs were
301 D3-10-D1-1 and D6-1-D1-1. D6-19 often served as D2, and D5-12 or D6-13 as D1. These findings
302 may shed light on the recombination mechanistic studies.

303 **Stochastic recombination contributes to the public clone**

304 Public clones are defined as to clonotypes shared by multiple individuals (Greiff et al., 2015; Jackson
305 et al., 2013; Miho et al., 2019). It has been suggested that public clones are valuable for designing
306 vaccines, monitoring the immune response to infection or vaccination, developing biomarker patterns
307 of disease states, and mediating the undesirable immune responses associated with autoimmune
308 diseases (Briney et al., 2019; Bürckert et al., 2017; Greiff et al., 2017; Maecker et al., 2012). Recent
309 studies reported that individuals exposed to the same antigen, such as HIV, influenza, or dengue, may
310 develop identical or similar Ig sequences – a phenomenon called antibody convergence (Jackson et al.,
311 2014; Parameswaran et al., 2013; Setliff et al., 2018; Truck et al., 2015). Thus, a comprehensive atlas
312 of public clones may help reconstruct the immunological history of an individual and may enable
313 immunotherapeutic targeting within a population with a specific disease.

314 Ig-seq has enabled public clone studies via multiple means. Greiff et al. developed an approach
315 that learned the high-dimensional immunogenomic features from the repertoire and enabled the
316 prediction of public and private clones (Greiff et al., 2017). By comparing multiple donors' ultra-deep
317 repertoire sequencing data, Burton et al. and Soto et al. estimated the fraction of public clones in an
318 individual to be approximately 1% and 1% to 6%, respectively (Briney et al., 2019; Soto et al., 2019).
319 Taking advantage of the unprecedented amount of data collected for the present study, we investigated
320 the prevalence of public clones in 2,152 samples. As shown in [Figure 5a](#), we found that the abundance
321 of public clones in a sample decreased when the total number of clones decreased. This result suggests
322 that methodological undersampling may compromise the detection of public clones (Greiff et al.,
323 2015). Furthermore, we also found that the number of public clones in two samples correlates linearly
324 with the product of their respective clone numbers ([Figure 5b](#)) and that this correlation improves when
325 the clone numbers for both samples increase ([Figure S11a-g](#)). The total number of clones in a given
326 volume of blood varies with an upper boundary. Thus, getting more clones requires more blood
327 samples. Based on different methods, the total clones in an individual's circulating blood has been
328 estimated to be between twenty-five million and one billion (Briney et al., 2019; Soto et al., 2019).

329 Using our linear models with a minimum number of 5 million clones, an individual may possess
330 between 4.2×10^4 and 6.87×10^7 public clones in his or her circulating blood.

331 More in-depth analyses revealed that V and J gene usage is almost identical to the gene usage for
332 all clones (Figure S12). On the other hand, public clones possess significantly shorter CDR3s (Figure
333 S13). Statistical analyses of the deletions, non-template additions, and P additions showed significant
334 differences in most elements between public clones and private clones (Figure S14). In particular, the
335 N1 and N2 additions in public clones between the VD and DJ junctions were shorter than those of
336 private clones. This may explain the short CDR3s in public clones and why D genes could not be
337 assigned in many public clones (Figure S15).

338 Of the 162,975 (transformed to the number of unique CDR3 amino acid sequences) public clones
339 identified in this study, 1,059 CDR3s were identical to published antigen-specific or
340 disease-associated antibodies (Figure S16a). Further analyses showed that these CDR3s are enriched
341 for the HIV, influenza, hematological malignancies, EBV, tetanus, and rheumatic categories (Table
342 S5). This enrichment confirmed that antibody convergence was a source of public clones. In addition
343 to the CDR3 enrichment in the antibodies with rheumatic autoimmune disease, we also found a CDR3
344 corresponding to SLE-specific antibodies in one of the healthy donors in our data. In addition, the
345 clonotypes shared by more donors were more abundant (Figure 5c), and this change in abundance was
346 not related to CDR3 length. Previous studies in T cell receptors (TCRs) found that shared TCRs are
347 more likely to be autoreactive (Madi et al., 2014) and that these autoreactive TCRs are important for
348 maintaining an individual's health. It is possible that public clones in an antibody repertoire serve the
349 same function. Surprisingly, we also found 31,226 (66.2%) IgM and 7,699 (70.7%) IgD clones with
350 identical sequences compared to their respective germline V and J genes (see Materials and Methods).
351 These clones are generated solely by VDJ recombination but have no somatic hypermutation,
352 regardless whether the individuals have been exposed to antigen or not. This result suggests that in
353 addition to antibody convergence, the stochastic nature of somatic recombination alone could be a key

354 mechanism of generating public clones. We believe this collection of public clones will be helpful for
355 studies relating to vaccine and therapeutic design targeting shared antibodies.

356 **Strand specificity features somatic hypermutation**

357 Somatic hypermutation (SHM) takes place in the germinal centers of peripheral lymphoid tissues
358 and increases the number of realizable antibodies by several orders of magnitude in addition to
359 combinatorial diversity. The preferences and patterns of SHM allow us to trace the clonal evolution of
360 antibodies under the selective pressure of particular antigen and to facilitate vaccine design (Schramm
361 and Douek, 2018). The nucleotides and amino acid sites that are preferred or disfavored in SHM have
362 been investigated using limited data and in model systems (Schramm and Douek, 2018). SHM in the
363 antibody repertoire results from two types of sequential events. First, activation-induced cytidine
364 deaminase and other molecular components of the SHM machinery introduce mutations to the
365 antibody variable regions. The selective pressure of a particular antigen then acts on these mutations
366 and preserves the favored ones. Thus, the majority of SHM studies worked from unproductive reads to
367 emphasize the effect of mutations rather than the effect of antigen selection. This is particularly
368 beneficial for mechanistic research on SHM because it simplifies the model. However, antigens only
369 place selective pressure on antibodies containing mutations and do not introduce additional mutations.
370 Despite some antigens that may preferably retain rare mutations, the clear majority of mutations in
371 functional antibodies would also reflect the selective flavors of the SHM machinery. Moreover, the
372 selective bias only acts on antigen-specific clones. Thus, this bias would be minimized if the effects of
373 clonal expansion are compensated or removed during computational analyses.

374 With this in mind, we used consensus sequences and a position weight matrix (PWM) to
375 represent a clone and probed mutations in the V genes at different levels ([Materials and methods](#)). We
376 first depicted the mutational propensities at the single nucleotide level ([Figures S17a and S17b](#)). Three
377 types of transitions (*A* to *G*, *G* to *A*, and *C* to *T*) occurred with high frequencies, and *T* to *C* mutations
378 occurred at a significantly lower frequency. Transversions between purines and pyrimidines were less
379 frequent, with the exception of *G* to *C* mutations. While *C* and *G* showed comparable mutability, *A*

380 exhibited significantly higher mutability than T. Because A: T and G: C present as pairs on the
381 chromosome and SHM occurs at the DNA level, it is interesting to observe that the mutational
382 tendencies are not reciprocal.

383 Having observed disproportional mutation tendencies in nucleotide pairs, we investigated the
384 mutability of reported motifs in a strand-specific manner (Material and methods). It is worth noting
385 that all nucleotides and motifs were extracted from the forward V gene sequences, and the reverse
386 sequences were discarded. Every nucleotide was classified exclusively in a single motif. Therefore,
387 the bases between categories have no overlap. We confirmed that SYC (where S is C or G; and Y is C
388 or T) and GRS (where R is A or G) are *bona fide* coldspots that showed the lowest frequency of
389 mutations. The motifs WRCY, RGYW, WA, and TW also showed much higher mutations than did
390 coldspots as reported by others (Liu and Schatz, 2009; Pham et al., 2003). However, significantly
391 different mutabilities were observed again between reciprocal motifs (WRCY and RGYW, WA and
392 TW) (Figure 6a, Figure S17c and Table S6). This result suggested strongly that SHM is introduced in
393 a strand-specific manner.

394 Complementarity-determining region (CDR) 1 and CDR2 exhibited higher mutations as expected
395 (Figure 6b and Figure S17d). While framework region (FR) 1 and FR2 displayed lower mutation rate
396 in contrast with CDRs, the region immediately adjacent to the CDR regions was also subjected to a
397 high frequency of mutations. These results support the idea that FRs provide the backbone of the
398 antibody, while CDRs accumulate mutations to achieve high affinity binding to a target antigen.
399 Consistent with previous observations (Shapiro et al., 1999), there was a considerable amount of SHM
400 in the FR3 region. Interestingly, the base with highest mutation rate was found near the end of the FR3.
401 A closer look at the germline sequence revealed that this nucleotide represents the third position
402 within a codon. The space for nucleotides, associated codons and amino acids was dominated by G,
403 GTG, and V (*valine*), respectively (Figures S18a-c). Interestingly, however, in most cases, this site
404 does not occupy any previously identified canonical hotspot (Figure S18d). Nucleotide substitution
405 analysis at this locus showed no preference and has no impact on the encoded amino acid except for
406 eight alleles in the IGHV5 gene family (Figures S18e-g and S18h). In addition, the mutation spectrum

407 profiles varied in different IGHV families (Figure 6c).

408 Although the conservative substitution (transition within the same amino acid group) dominated
409 amino acid substitution profile, we observed relatively-high frequencies for non-conservative
410 substitutions, such as *H* to *Y* and *N* to *D*, that were not identified before using limited number of
411 datasets. In addition, we found *W* and *C* were least mutated (3.95% and 1.63%) and mutated to (1.00%
412 and 2.17%) (Figure 6c and Figure S17e).

413 The level of SHM as a function of confounding factors, such as age, sex, and isotypes, has also
414 been explored to some extent (Jiang et al., 2013; Kitaura et al., 2017; Wang et al., 2014). Nonetheless,
415 there have been no studies to date profiling SHM from a large data set. Using 363 samples from 290
416 donors, we reviewed the role of age, sex and isotypes on the frequency of SHM. We found negligible
417 differences between males and females, except for those between 41-50 years of age which probably
418 result from uncommon sampling bias. (Figure S19). We therefore combined data from male and
419 female donors to investigate the effects of age and isotype. Switched isotypes, namely IgG, IgA, and
420 IgE, had comparable level of SHM (7 - 8%), while IgM and IgD had much lower level of SHM (1 -
421 2%) (Figure S20), consistent with a previous report (Kitaura et al., 2017). We also observed a positive
422 correlation between the level of IgG SHM and age, except for individuals in the 41-50 age range
423 (Figure 6e). When we measure the contribution of age to SHM levels using a linear model, we
424 obtained r-square values of 0.37 and 0.28 for male and female, respectively. Despite the compromised
425 goodness of the model, we confirmed this correlation at the population level and estimated that the
426 SHM increases by approximately 0.05% each year. This increase would mean that in general, a parent
427 bears 1% more SHM than their children (Figure 6f).

428

429 Discussion

430 Extremely large data sets have proven to be powerful for computational analysis to reveal
431 patterns, trends, and associations. The advent and application of high-throughput sequencing

432 technology advanced the study of complex biological systems, launching projects such as the 1000
433 Genomes Project, The Cancer Genome Atlas, the Encyclopedia of DNA Elements, and the NIH
434 Human Microbiome Project. Inspired by the success of these projects, we systematically analyzed the
435 largest antibody repertoire dataset to date and scrutinized, for the first time at this scale, the key
436 features of the antibody repertoire.

437 In addition to the uneven usage of germline genes, we identified a set of core V genes that
438 contribute to the clear majority of the repertoire. Although the other V genes are less frequently
439 observed in the current datasets, we believe their absence is the result of shallow sequencing depth
440 compared to the complexity of antibody repertoire. Nonetheless, these core and “rare” V gene sets
441 may serve as a reference for discovering gene usage fluctuations that are associated with or specific to
442 particular diseases. We found that the number of public clones between two repertoires also relied on
443 the sequencing depth. Moreover, a fraction of public clones identified in repertoire comparisons were
444 reported to be disease-associated or antigen-specific. This result supports the notion of antibody
445 convergence and also suggests that the antibody repertoire may help us trace an individual’s immune
446 history and may therefore be useful in selecting vaccines and immunotherapy for certain diseases.

447 The fundamental B cell biology that underlies the specific patterns of germline usage, D-D fusion,
448 and SHMs revealed in our analyses remains controversial. Follow-up experiments may reveal the
449 mechanisms behind these phenomena and thus advance our understanding of B cell development as
450 well as its response to immune perturbations.

451 Due to the intrinsic amplification bias caused by different amplification strategies and various
452 primer sets, we did not perform analyses of clonal expansion, diversity, and evenness. A common
453 standard for both experimental design and bioinformatics analysis will be critical for future studies.

454 The human antibody repertoire possesses extreme diversity. Compared to the aforementioned
455 prior studies, the number of samples analyzed here is far from sufficient to capture all this diversity.
456 Moreover, antibody repertoires from a broad spectrum of diseases as well as different isotypes from
457 various tissue types are still needed for a better understanding of humoral immunity. Due to the

458 limited source of human samples, it is likely that further studies with model systems such as mouse,
459 rat, and macaque will bring us more insights.

460 **Acknowledgements**

461 This study was supported by the National Natural Science Foundation of China (NSFC) (31771479)
462 (Z. Z.), NSFC Projects of International Cooperation and Exchanges of NSFC (61661146004), the
463 Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program
464 (2017BT01S131), the Thousand Talent Plan of China, and the Guangdong Natural Science Funds for
465 Distinguished Young Scholar (2017A030306030), the Guangdong Innovative and Entrepreneurial
466 Research Team Program (2016ZT06S638), the National High Technology Research and Development
467 Program of China (2012AA02A206), National Natural Science Foundation of China (NSFC)
468 (81822036 and 31770931) (W. Y.), the National Science Foundation for Excellent Young Scholars
469 (81222035), the National Program for Support of Top-Notch Young Professionals (X. B.), the Chang
470 Jiang Scholars Program (X. B.), the Special Support Program of Guangdong (X. B.).

471 **Author Contributions**

472 X. Y., Y. Z., H. Z., Y. Z., C. L., J. W., C. M., and Y. Z. performed the bioinformatics analyses on the
473 data. M. W., D. S., C. L., Y. D., S. G., L. X., R. W., and J. O. collected blood samples and conducted
474 the biological experiments. M. W., S. G., R. W., and C.J. L. prepared the libraries and performed
475 Illumina sequencing. C. C., W. Y., H. Z., J. C., L. Q., H. Z., J.X. B., L. W., G. C., X. Y. and Z. Z.
476 designed the project, biological experiments as well as bioinformatics analyses. X. Y., M. W., D. S., Y.
477 Z., H. Z., Y. Z., C. L., G. C., X. Y. and Z. Z. co-wrote the manuscripts.

478 **Declaration of Interests**

479 The authors declare no competing financial interests. China Patents No. CN2019104688441,
480 CN2019104688441, and CN2019104688579.

481 **Figure titles and legends**

482 **Figure 1. Overview of the enrolled datasets.** (a) The number of samples in each enrolled project.
483 The X axis shows NCBI SRA project IDs, and ZZHLAB indicates the antibody repertoires generated
484 in our lab. The Y axis shows the log₁₀ transformed number of samples. The numbers of samples
485 excluded by data size and experimental design are shown in red and grey, respectively. (b, c, d, e, f)
486 show sample distribution based on (b) age; (c) sex; (d) PCR amplification strategy; (e) classification
487 (healthy or diseased); and (f) various tissue or blood.

488 **Figure 2. Germline gene usage and core V genes.** (a) The heatmaps show the normalized usage of V
489 (top panel), D (middle panel), and J (bottom panel) genes. Each column shows color-coded gene
490 usage for a dataset. Each row shows usage pattern of a particular gene (IDs labeled on the left side) in
491 different datasets. The bar graphs to the right of the heatmaps show the number of samples in which
492 each gene was present. J genes were present in almost every sample. The bar graph on top of the V
493 gene usage heatmap shows the number of V genes present in each sample. (b) and (c) The V genes
494 were ordered based on their occurrences in 582 individuals from high (left) to low (right). The X-axis
495 shows the number of high frequency V genes included. (b) The Y-axis shows the percent of total
496 clones that were represents by the most frequent V genes shown on X-axis. The color shows the log
497 ₁₀ transformed number of samples each pixel represents. (c) The red line indicates the median
498 fractions of total clones that were represents (left Y-axis) by the inclusion of top number of clones
499 shown on X-axis. The blue line represents the slope of median clone fraction variation (on the red line)
500 based on the adjacent 10 data points, 5 on the left and 5 on the right.

501 **Figure 3. Gene usage patterns with regard to genetic background, age, and gender.** (a) The
502 Pearson's correlation (Pearson's r) distribution of the gene usage between 5,261 paired samples. The
503 Pearson's r values were ordered from low to high. The red and light pink lines represent Pearson's r
504 values calculated using all V genes and 53 core genes, respectively. The blue and green dots indicate
505 the Pearson's r values between same and different cell types for monozygotic twins, respectively. (b)
506 The relationship between core V genes and ages. The X-axis shows V gene ordered by frequency

507 (Table S1). The Y-axis indicates the R2 values calculated for a particular V gene at different ages
508 (Supplementary. Fig. 6 and Materials and methods). (c), (d) and (e) show comparisons of core V (c),
509 D (d), and J (e) genes between male and female. The red triangles indicate genes whose usage was
510 significantly different between sexes.

511 **Figure 4. Recombination and modification between V(D)J recombination.** (a) Recombination
512 count and frequency of different VD/DJ segments. The logarithm of the count is shown by the color of
513 the points, and the frequency of recombination is shown by the size of the points. The line at the
514 margin shows the number of each gene segment. V genes, core genes and non-core genes are marked.
515 The arrow shows the direction in IGH locus. (b) Distribution of CDR3 length in all sample, clones
516 with whole V, D, J assignment, and DD fusion. (c) Frequency of DD fusion in each isotype. The line
517 plot shows the number of samples with at least 5,000 clones in each isotype. (d) D gene usage in DD
518 fusion. (e) Frequency of DD fusion with different span; the span of adjacent D gene is 1. (f) The
519 number of DD fusions in all clones. The x axis represents the D gene at the 5' end, and the y axis
520 represents the D gene at the 3' end. The bar plot at the margin shows the number of each row or
521 column.

522 **Figure 5. Inter-sample abundance and gene usage of public clones.** (a) The heatmap in the center
523 indicates the abundance of public clones between samples. The top bar chart indicates the number of
524 recovered total clones for each sample. The number of public clones between each pair of sample has
525 been subjected to logarithmic transformation ($T=\log(1+Pab)$). The number of public clones between
526 samples within the same project has been set to 0 to remove chimera-related effects. Note that some
527 samples from PRJNA260985 and PRJNA280743, were predicted to come from the same donors and
528 the observed public clones between these samples was set to 0. (b) Linear model delineating the
529 correlation between inter-sample public clone abundance and the product of their clone abundance. (c)
530 Public clone size percentage as a function of donor sharing count.

531 **Figure 6. Somatic hypermutation patterns and influence factors.** (a) The stacked column diagram
532 shows the mutation percentage of motifs and composition of mutation targets. The X axis shows the

533 different motifs in germline sequences. The Y axis shows the composition of the mutated nucleotide
534 of this motif. The line chart shows the mutation fraction of every motif. The red-colored label
535 represents hot-spot, the blue colored label represents cold-spot. The underlined letter represents the
536 mutation site. **(b)** and **(c)** show the mutation rate among different functional alleles and families. **(b)**
537 The combined heatmap shows the mutation rate among used functional alleles in selected IgG samples.
538 Each column shows the position of completion of the V segment from FR1 to FR3. Each row shows
539 the functional alleles occurred in datasets. The area chart represents the average mutation rate in every
540 position. The bar graph left to the heatmap shows the family of occurred alleles which ordered by the
541 number of clones who were shows in the right bar graph. The color of the heat map represents the
542 mutation rate of every position from used functional alleles. **(c)** The X axis shows the position of the
543 V segment from FR1 to FR3. The Y axis shows the average mutation rate from different families. The
544 area chart shows the overall average mutation rate about used functional alleles. The red lines and blue
545 dotted lines show the result of the mutation rate of every family based on consensus and weight matrix
546 methods. **(d)** The combined heatmap shows the substitution among amino acid. Each column and each
547 row represents an amino acid. The germline residue is located on the x axis, and the mutated amino
548 acid is located on the Y axis. The line graph represents the ability of each amino acid to be mutated
549 and mutated. **(e)** The boxplot shows the mutation rate for different age groups across multiple
550 functional region and whole region. The points on top of each boxplot indicates the outliers. **(f)** The
551 scatter plot (orange for male and blue for female) shows the correlation between mutation rate and age.
552 Two lines in the figure are the predicted linear regression model for male and female. R-squared value
553 were marked on the top left in this figure.

554

555 **Materials and Methods**

556 **Dataset enrollment criteria**

557 We searched for bioprojects that were related to the antibody repertoire on the Sequence Read Archive
558 (SRA: <https://www.ncbi.nlm.nih.gov/sra>) from the National Center for Biotechnology Information
559 (NCBI: <https://www.ncbi.nlm.nih.gov/>). We identified thirty-eight projects before Feb 28, 2019. The
560 datasets from the included projects were subjected to two consecutive filter processes. The first filter
561 procedure was based entirely on sample metadata provided by SRA and the corresponding papers. The
562 criteria include:

- 563 ● Homo sapiens
- 564 ● Illumina platform
- 565 ● Pair-end Library Layout
- 566 ● Sequencing length ≥ 250
- 567 ● Natural sample directly extracted from human tissues (excludes those samples derived from cell
568 lines)
- 569 ● No specific amplification
- 570 ● Library source is either GENOMIC or TRANSCRIPTOME
- 571 ● No spike-in sequences

572 The second filter procedure was based on the results when preprocessing finished, criteria here
573 consists of,

- 574 ● Number of productive reads for heavy chain $\geq 10,000$
- 575 ● Fraction of heavy chain $\geq 20\%$

576 **In-house dataset**

577 **Subjects**

578 A total of 295 peripheral blood mononuclear cells (PBMCs) samples were collected. Of these, 254
579 were derived from healthy individuals (without recent infection events), 18 were from HBV patients,
580 16 were from H7N9 patients, 6 were from individuals involved in traffic accidents, and 1 was from a
581 patient with meningitis. Peripheral blood samples (1 ml) obtained from each volunteer were collected
582 in an EDTA-containing sterile tube and stored at room temperature for no more than 6 hours. PBMCs
583 were isolated by Ficoll-Paque density centrifugation using Lymphoprep™ (Axis-Shield, 1114547),
584 and the isolated cells were lysed in RLT buffer (Qiagen) supplemented with 1% β -mercaptoethanol
585 (Sigma) before being stored in -80°C for short-term storage. This protocol was approved by the Ethics
586 Committee at Southern Medical University. Informed consent was obtained from all participants.

587 **RNA extraction, reverse transcription, 5'RACE amplification, and next-generation sequencing** 588 **procedures**

589 RNA purification was carried out using the RNeasy Mini Kit (Qiagen, 74106) according to the
590 manufacturer's instructions. The concentration of the RNA was determined using a NanoDrop 2000c
591 Spectrophotometer (ThermoFisher Scientific). Five hundred nanograms of RNA purified from each
592 sample was used for cDNA synthesis with a total volume of 20 μ l. cDNA was prepared using a
593 SMARTer RACE cDNA Amplification Kit (Clontech, 634928) according to the manufacturer's
594 instructions. Forward primers were synthesized according to SMARTer RACE protocol. The first 50
595 bp of the first constant domain (CH1) of heavy chain (IgG) were used to design the reverse primers.
596 We also designed 8-11bp barcode at the upstream of these primers to distinguish samples. One
597 microliter of the reverse transcription mixture was used as a template in a 20 μ l PCR reaction. Primers
598 were used at a final concentration of 100 nM. The thermal cycling conditions were programmed as
599 follows: denaturation at 95°C for 3min, 30 cycles of denaturation at 98°C for 20s, annealing of primer
600 to DNA at 60°C for 15s, and extension by Kapa HiFi HotStart Ready Mix (KAPA Biosystems, kk2602)
601 at 72°C for 15s, followed by a final extension for 5 min at 72°C. PCR products were analyzed on a 1.5%

602 agarose gel, and the appropriate bands (~600 bp) were purified using the Nucleospin Gel & PCR
603 Clean-up kit (Macherey-Nagel, 704609.25). DNA Concentration was measured using the NanoDrop
604 2000c Spectrophotometer (Thermo Fisher Scientific), and 400 ng of DNA was used to prepare
605 libraries using a Universal DNA Library Prep Kit for Illumina V3 (Vazyme, ND607-01), strictly
606 following the manufacturer's instructions. Libraries were quantified using the Qubit 4.0 fluorometer
607 (ThermoFisher Scientific) and re-quantified using the KAPA qPCR kit (KAPA Biosystems, 4824). The
608 size of adapter-ligated DNA fragments (approximately 800 bp) was determined using a Bioanalyzer
609 2100 system (Agilent). Each library was subjected to 2×300 bp paired-end sequencing using MiSeq
610 Reagent V3 kits (Illumina, MS-102-3003).

611 **Germline gene assignment and clonotype assemble**

612 Paired-end FASTQ files downloaded from SRA and generated by our laboratory were inputted into
613 *MiXCR* (version 3.0.7) and run with the following parameters:

614 Align: *mixcr align --library my_library -t 8 -r align_log.txt R1 R2 alignments.vdjca -s hs*

615 Assemble: *mixcr assemble -r assemble_log.txt -OseparateByV=true -OseparateByJ=true -Osepar*
616 *ateByC=true alignments.vdjca clones.clns*

617 Export clones: *mixcr exportClones clones.clns clones.txt*

618 Export Alignments: *mixcr exportAlignments -f -readIds -vHit -dHit -jHit -cHit -vGene -dGene*
619 *-jGene -nFeature CDR3 -aaFeature CDR3 -defaultAnchorPoints alignments.vdjca alignments.txt*

620 We built germline references for V, D, J, and C gene segments locally, and the germline refe
621 rences for V, D and J gene used in this study were customized using *repseqio* (v1.2.12, <https://github.com/repseqio/repseqio>). Reference sequences were obtained from IMGT/GENE DB (<http://www.imgt.org/genedb/>) and are provided in [Table S7](#). The formatted information for the re
623 ference constant region sequences was directly extracted from the *MiXCR* built-in reference (v
624 1.5) and then appended to the formatted customized reference for V, D and J genes. *MiXCR*
625 clustered sequences with the same V, J, and C allele assignment and CDR3 nucleotide sequen
626

627 ce into a clone with the parameters above. An in-house *Python* script was used to merge clo
628 nes with the same V and J gene and CDR3 nucleotide sequence into a clone. If we investiga
629 ted isotypes effect on some indices such gene usage, the C gene was also taken consideration.
630

631 **Comparison of gene usage and expression between Multiplex and RACE**

632 Gene usage was defined as the number of clones with a given gene segment divided by the total
633 number of clones. Gene expression was defined as the number of reads with a gene divided by the
634 number of productive reads. For each gene segment, the median of usage and expression for either
635 Multiplex or RACE was used for linear regression. Usage or expression from Multiplex was defined
636 as independent variable while that from RACE was considered as dependent variable. The *regplot*,
637 *r2_score*, and *pearsonr* functions in *seaborn* (version 0.9.1) and the *sklearn* (version 0.20.2) and *scipy*
638 (version 1.2.1) *Python* modules were used to visualize the linear regression and to calculate R squared
639 values and a Pearson Correlation Coefficient.

640 **Overview and core gene set selection of gene usage**

641 To show gene usage for all 2,152 samples clearly, we set thresholds for V, D, and J genes. If the usage
642 was greater than the threshold, we used the threshold value instead of the original value. The average
643 of the maximum of each sample for V, D, and J gene were calculated as thresholds. For core V gene
644 set selection, we first sorted genes according to their occurrence in 582 donors. We then enrolled 102
645 V genes one by one and computed the accumulated clone fraction with specific V genes for 2,152
646 samples. The median of clone fraction for all samples was selected and the slope of them was
647 computed. The slope of x_i was equal to the distance of clone fraction at x_{i-5} and x_{i+5} divided by 11.
648 Finally, if the slope was less than 0.001, we determined the clone fraction arrived the plateau and
649 chose this gene set as the core gene.

650 **Features' effect on gene usage**

651 **Genetic background**

652 Two hundred and twenty-two healthy peripheral blood mononuclear cell samples, obtained from 29
653 male and 22 female individuals from 21 to 30 years of age, were amplified by RACE and used to
654 explore how genetic background affects gene usage. We examined two gene sets containing 53 core V
655 gene and 102 V genes. The Pearson Correlation Coefficient for every sample pair was calculated
656 using *pearsonr* from a Python module named *scipy* (version 1.2.1). Sample pairs from the same donor
657 were excluded. We performed statistics for male and female samples separately.

658 **Age**

659 We chose 499 healthy PBMC samples drawn from 94 male donors and 164 female donors by RACE.
660 Linear regression was conducted using *LinearRegression* and *r2_socre* from *sklearn* (version 0.20.2)
661 module. The independent and dependent variables were age and gene usage (of 53 V genes, 34 D
662 genes, and 6 J genes), respectively. Samples derived from males and females were analyzed
663 separately.

664 **Sex**

665 We performed two independent sample t-tests for 53 V genes, 34 D genes, and 6 J genes on the 499
666 samples selected above using *ttest_ind* from *scipy* (version 1.2.1). Genes whose P values were less
667 than 0.05 were defined as differentially used in the male samples and the female samples.

668 **Isotype**

669 We first obtained isotypes composition including IgA, IgD, IgE, IgM, and IgG for the 499 samples
670 above. Because the fraction of IgE was too low to compare, we discarded this isotype. Based on the
671 isotype fraction, there were 14 female and 37 male samples that could be used for this analysis. We
672 then merged clones for each isotype from different samples derived from the same donor and
673 recalculated gene usage for them. Gene usage was regarded as a vector, and *Euclidean distance* was
674 calculated using *DistanceMatrix* from *scikit-bio* (version 0.5.5) to measure the similarity of gene

675 usage between different isotypes. The *nj* function from *scikit-bio* was used to build a neighbor joining
676 tree. Finally, we used *Dendroscope* (version 3.6.3) to generate the trees. Samples analyzed for gene
677 usage related to genetic background, age, and so on, are shown in [Table S8](#).

678 **VD/DJ recombination**

679 To compare the recombination bias in all clones, we only analyzed clones with a D gene assignment.
680 Clones with full V, D, J gene assignments were pooled together. Clones without stop codons or out-of
681 –frame mutations in the CDR3 region were considered to be productive clones. If multiple
682 assignments occurred, the gene with the highest score was used for the analysis. The clones were
683 separated into subgroups according to VD/DJ recombination, and the frequency of each group was
684 calculated. The number of each gene was calculated according to about 352 million productive clones.

685 **D-D fusion detection**

686 *IgScout* was used to detect D-D fusion. Input files were extracted from the *MiXCR* results using a
687 custom generated script, which used default parameters and the same reference as *MiXCR*. No other
688 filter was used to detect D-D fusion. The identity of D-D fusion and alignment length were calculated
689 by a custom script written in python. Levenshtein distance was used to quantify the difference
690 between the reference and the aligned sequences. The length of the aligned sequence was calculated
691 directly from the result of *IgScout*.

692 **Position bias in D-D fusion**

693 Tandem CDR3s from all samples were pooled together to calculate gene usage in all D-D fusions. We
694 defined D1 as the D gene at the 5' end and D2 as the D gene at the 3' end. The span of two D genes
695 was defined as the genes position number between 5' D and 3'D on the corresponding chromosome.
696 The span of two adjacent D genes was 1. A negative value indicated that the D1 gene was located at
697 the 5' end of D2 on the chromosome, and a positive value represented a D2 gene located at the 3' end
698 of D1 on the chromosome.

699 **Comparison of D-D frequency between isotypes**

700 To compare the D-D frequency between isotypes, we also included C gene annotations. Due to the low
701 frequency of D-D fusion, we only included samples that contained at least 5,000 clones for
702 corresponding isotypes. Our analysis included 104, 594, 489, 163 samples for IgD, IgM, IgG, and IgA,
703 respectively. IgE was not included in the analysis because none of the samples met our criteria of at
704 least 5000 annotated clones. The frequency of D-D fusion in each sample was calculated as the
705 number of D-D fusions in the corresponding isotype divided by the total number of corresponding
706 isotypes.

707 **CDR3 length distribution**

708 The number of nucleotides in each clone was defined as the CDR3 length of the clone. The
709 distribution of all clones was showed calculated from total clones. CDR3 clones with a D gene
710 assignment were calculated as D-containing CDR3. The length of Tandem CDR3s was calculated
711 from an output file named tandem_cdr3s.txt generated by *IgScout*. To make the distribution
712 comparable, the frequency of CDR3s in each length group was used.

713 **Public clone abundance profile**

714 Public clones were those clonotypes (defined before) shared by at least two donors from two or more
715 projects. Therefore, number of public clones between two samples from the same project or the same
716 donor was set to zero. This strict criterion for clonotypes was applied to remove ‘public’ clones
717 resulting from chimeric artifacts.

718 **Linear model to delineate the stochastic nature of gene recombination**

719 Linear models were constructed using only valid sample pairs that derived from different donors in
720 different projects. Associated coefficients for regression equation and R squared were estimated using
721 function *linear_model.LinearRegression* within the Python package *sklearn* (version 0.20.2).

722 **Profile of gene usage, CDR3 length, and Junctional Modification**

723 Non-redundant public clones were used to profile gene usage and CDR3 length distribution, while
724 redundant public clones were used for junctional modification analysis. The junctional modification
725 calculation method is the same as above. Statistical analysis was carried out using a two-tailed
726 unpaired Student's t-test.

727 **Antigen- or disease-related antibody database overlapping**

728 We generated custom antigen- and disease-related antibody databases (unpublished results). All
729 curated antibody sequences (heavy chain) were collected from following databases: i)
730 IMGT/LIGM_DB (<http://www.imgt.org/ligmdb/>); ii) abYsis
731 (<http://www.bioinf.org.uk/abysis3.1/index.html>); iii) EMBLIG
732 (<http://acrmwww.biochem.ucl.ac.uk/abs/abybank/emblig/>); iv) bNAber (<http://bnaber.org/>), v)
733 HIV_DB (<http://www.hiv.lanl.gov/>); vi) NCBI Nucleotide database
734 (<https://www.ncbi.nlm.nih.gov/nucleotide/>); and vii) EBI ENA (<https://www.ebi.ac.uk/ena>). For now, it is
735 comprised of 65,088 non-redundant antibody heavy chain sequences, corresponding to 53,579 unique
736 CDR3 amino acid sequences and 163 types of antigen or disease, including HIV, hematological
737 malignancies, preterm birth, influenza and etc. Antigen- or disease-related enrichment analysis of
738 overlapping antibodies was performed using a hypergeometric model, implemented with the
739 *stats.hypergeom.cdf* function within the Python package *scipy* (version 1.2.1). The false discovery rate
740 was calculated using the *Benjamini-Hochberg* method implemented with an in-house script.

741 **Somatic hypermutation**

742 **Sample selection**

743 Only samples which were from healthy donors' PBMC and were amplified using RACE protocol
744 were included in the somatic hypermutation analysis. Since some experimentally qualified datasets

745 with which the alignment information failed to be exported, 363 samples were included in the end
746 (Table S8).

747 **Export alignment**

748 Alignment information used to measure somatic hypermutation was exported using *MiXCR* with the
749 following parameters:

750 Assemble: *mixcr assemble -r assemble_log.txt -OseparateByV=true -OseparateByJ=true*

751 *-OseparateByC=true -a alignments.vdjca clones.clna*

752 Export Alignments: *mixcr exportAlignments -f -readIds -cloneId -vHit -vAlignment -jHit -jAlignment*

753 *-cHit -cAlignment -nFeature FR1 -nFeature CDR1 -nFeature FR2 -nFeature CDR2 -nFeature FR3*

754 *-nFeature CDR3 -nFeature FR4 -aaFeature FR1 -aaFeature CDR1 -aaFeature FR2 -aaFeature*

755 *CDR2 -aaFeature FR3 -aaFeature CDR3 -aaFeature FR4 -defaultAnchorPoints clones.clna*

756 *alignments.txt*

757 **Quality filtering and data preprocessing:**

758 (1) Read QC. Removal of reads that could not be merged by *MiXCR*, those without complete
759 variable regions (VR), those having been assigned with a pseudogene or a different V assignment
760 compared with their corresponding clones', those containing insertions or deletions and those
761 with stop codons or frameshifts in the variable region.

762 (2) Clone QC. Removal of clones with only single qualified reads following read QC procedure
763 above.

764 (3) VR deduplication. Deduplicating VR to obtain non-redundant sequence set

765 (4) VR grouping. Grouping VR according to the isotypes reported in the clone files.

766 **Implementation of consensus and position-weighted matrix approaches**

767 The position-weighted matrix approach considers all qualified non-redundant reads within each clone.
768 Because each clone was a basic unit in the somatic hypermutation analysis, the mutation rate for a
769 certain position was calculated as the sum of mutation rate for all mutation events observed within
770 reads supporting this clone. The number of substitution types for a nucleotide (nt) or an amino acid (aa)
771 for a certain position was defined as 1 if a nucleotide or amino acid in a given position underwent the
772 same substitution event for all reads within a clone (with the same target nt or aa), otherwise it would
773 have a value less than 1.
774 For every clone, a theoretical consensus sequence was calculated based on the *motifs* module in
775 *Biopython* (version 1.73). The Hamming distance was used to calculate the distance between the
776 theoretical sequence and each true sequence, where the true sequence closest to the theoretical
777 sequence was taken as the representative sequence of the clone.

778 **Software**

779 In-house scripts were written in Python (version 3.7.4) based on the numpy (version 1.16.4),
780 Biopython (version 1.73), Levenshtein (version 0.12.0) and pandas (version 0.24.2) modules. To
781 visualize these results, we used the Python modules seaborn (version 0.9.1) and matplotlib (version
782 3.0.2) as well as GraphPad Prism (version 7.04).

783 **Supplemental Information titles and legends**

784 **Figure S1. Age (a) and sex (b) composition of enrolled donors.** Total number of enrolled
785 donors is 582.

786 **Figure S2. The Pearson correlation coefficients of gene expression and usage between**
787 **Multiplex and RACE.** Left: the distribution of Pearson correlation coefficients of V (a), D (b),
788 and J (c) gene expression between Multiplex and RACE. Right: Pearson correlation coefficients

789 of V (d), D (e), and J (f) gene usage between these two groups. Note: There are 1,409 datasets
790 amplified by Multiplex and 743 datasets amplified by RACE.

791 **Figure S3. Fraction of repertoire containing the 53 core V genes.**

792 **Figure S4. Number of uncaptured V genes for 109 male (a) and 113 female (b) samples.**

793 **Figure S5. The Pearson correlation coefficients of D (a), J (b) for male and V (c), D (d), and**

794 **J (e) for female.** Lines in red show all genes, and the line in light purple shows the core V genes.

795 The dots indicate monozygotic twins from PRJNA300878. The blue dots indicate the same cell

796 type of monozygotic twins, and the green dots indicate different cell types (naïve and memory)

797 for them.

798 **Figure S6. Effect of Age on gene usage for females and males.** The R square of linear

799 regression between D (a), and J (b) gene usage and age in female. (c) The scatter plot for 53 V, 34

800 D, and 6 J genes usage and age. The X-axis means the age and the Y-axis stands for the usage. R

801 squared for V (d), D (e), and J (f) usage and age in the male.

802 **Figure S7. Gene usage in the infected and uninfected samples of the female (a, b, and c) and**

803 **male (d, e, and f).** Boxplots show usage from uninfected samples, while the red dots represent

804 usage from infected ones.

805 **Figure S8. The isotype composition of clone from the male (a) and the female (b).** Each

806 column shows one isotype including IgA, IgD, IgE, IgG, IgM, and None, and each row represents

807 a sample. For the row side color at the left of heatmap, the leftmost one was used to mark an

808 individual while the right one was used to distinguish a project. Note: None means those clones

809 cannot be aligned to a C gene.

810 **Figure S9. Clustering of V (a), D (b), and J (c) gene usage with different isotype in the male.**

811 IgA was labeled in light blue, IgG was filled in blue, IgD was colored in light green, and IgM was
812 labeled in green.

813 **Figure S10. Clustering of V (a), D (b), and J (c) gene usage with different isotype in female.**

814 IgA was labeled in light blue, IgG was filled in blue, IgD was colored in light green, and IgM was
815 labeled in green.

816 **Figure S11. Linear model for describing the correlation between number of public clones**

817 **and product of numbers of clones with each sample pair.** Only sample pairs with both clone
818 number being greater than (a) 10,000, (b) 100,000, (c)1,000,000, (d) 2,000,000, (e) 3,000,000, (f)
819 4,000,000 and (g) 5,000,000 were selected to demonstrate the correlation. The regression
820 functions are at the top of figures. Selected sample pair that with more clones show more fitness
821 of the linear model.

822 **Figure S12. Public clone gene segment usage.** (a, b) The two barplots show V and J gene usage

823 frequency between public and private clones. Gene segments have been sorted by overall
824 frequency and for v gene only those comprised more than 1% of the total repertoire were listed
825 here. (c, d) The scatter plot demonstrated gene usage frequency correlation between public and
826 private clones. The top left value (ρ) indicates Pearson's correlation coefficient.

827 **Figure S13. CDR3 nucleotide length distribution comparison between total productive**

828 **clones (n=267,761,654) and unique public clones (n=429,157).** Note that the upper limit for
829 length is determined according to a threshold of 1%. Two-sample Kolmogorov-Smirnov tests
830 were performed to investigate length distribution difference (P-value <1.149e-13).

831 **Figure S14. Junctional modification comparison between total clones from 2,165 samples**

832 **and public clones.** The boxplot in each subfigure demonstrates the distribution of each kind of

833 junction modification length, as indicated by the schematic in bottom right (a). (b) Non-templated
834 insertion length. (c) Palindromic insertion length distributions. (d) Deletion length distributions.

835 **Figure S15. Percent of clones with D hit(s) for 2,165 samples and all public clones.** The
836 boxplot on the top demonstrates the percent distribution for 2,165 samples (with a median of
837 97.9%), and the red point at the bottom indicates the percent for public clones (67.6%).

838 **Figure S16. Antigen-specific or disease-associated annotation of public clones.** (a)
839 Overlapping of unique clonotypes between public clones and antibody sequences curated with
840 related antigen or disease information. A clonotype here was defined as a unique CDR3 amino
841 acid sequence with deprecated conserved residuals at both ends. (b) Disease or antigen percentage
842 of annotated public clones. Terms in the same line in the legend are indicated by same color.
843 Terms in legend match the pie chart from top to bottom and from left to right.

844 **Figure S17. Somatic hypermutation patterns and influence factors.** (a) and (b) represent the
845 transform among nucleotides based on the algorithm of consensus and position weight matrix
846 (PWM). Each column and each row represent a nucleotide. The germline nucleotide is located on
847 the x axis and the mutated nucleotide is located on the Y axis. The total mutation rate and target
848 preference of every nucleotide are marked in the figure. (c), (d) and (e) used position weight
849 matrix (PWM) to describe the patterns of somatic hypermutation.

850 **Figure S18. Description of the 290th position, which has the highest mutation rate.** (a), (b),
851 (c), and (d) show the composition of nucleotide, amino acid, codon, and motif in the germline
852 sequence sorted by ratio, respectively. (e), (f) and (g) showed the fraction and composition of
853 mutation from different families. (h) The boxplot shows the comparison of mutation rate between
854 synonymous mutations and nonsynonymous mutations from different families.

855 **Figure S19. Mutation rate comparison between male and female based on IgG clones.** (a-e)
856 were based on consensus approach and (f-k) were based on PWM approach. Comparison were

857 performed independently in different age groups to remove age-related effect (marked on the top
858 right of each subfigure). and only those age groups with at least 10 donors for both genders were
859 presented here. The four numbers following each isotype in figure legends represent the number
860 of clones, samples, donors and projects, respectively.

861 **Figure S20. Mutation rate comparison between different isotypes.** (a-c) were based on
862 consensus approach and (d-f) were based on PWM approach. Comparison were performed
863 independently in different age groups to remove age-related effect (marked on the top right of
864 each subfigure). Only 3 age groups have two or more kinds of clones. The four numbers
865 following each isotype show the number of clones, samples, donors and projects, respectively.

866

867 **References**

868 Bonsignori, M., Zhou, T., Sheng, Z., Chen, L., Gao, F., Joyce, M.G., Ozorowski, G., Chuang, G.Y.,
869 Schramm, C.A., and Wiehe, K., *et al.* (2016). Maturation Pathway from Germline to Broad HIV-1
870 Neutralizer of a CD4-Mimic Antibody. *CELL 165*, 449-463.

871 Boyd, S.D., Gaeta, B.A., Jackson, K.J., Fire, A.Z., Marshall, E.L., Merker, J.D., Maniar, J.M., Zhang,
872 L.N., Sahaf, B., and Jones, C.D., *et al.* (2010). Individual variation in the germline Ig gene repertoire
873 inferred from variable region gene rearrangements. *J IMMUNOL 184*, 6986-6992.

874 Briney, B., Inderbitzin, A., Joyce, C., and Burton, D.R. (2019). Commonality despite exceptional
875 diversity in the baseline human antibody repertoire. *NATURE 566*, 393-397.

876 Briney, B.S., Willis, J.R., Hicar, M.D., Thomas, J.W., and Crowe, J.E. (2012). Frequency and genetic
877 characterization of V(DD)J recombinants in the human peripheral blood antibody repertoire.
878 *IMMUNOLOGY 137*, 56-64.

879 Briney, B.S., Willis, J.R., McKinney, B.A., and Crowe, J.J. (2012). High-throughput antibody
880 sequencing reveals genetic evidence of global regulation of the naive and memory repertoires that
881 extends across individuals. *GENES IMMUN 13*, 469-473.

882 Bürckert, J., Dubois, A.R.S.X., Faison, W.J., Farinelle, S., Charpentier, E., Sinner, R.,
883 Wienecke-Baldacchino, A., and Muller, C.P. (2017). Functionally Convergent B Cell Receptor
884 Sequences in Transgenic Rats Expressing a Human B Cell Repertoire in Response to Tetanus Toxoid
885 and Measles Antigens. *FRONT IMMUNOL* 8.

886 Chothia, C., Lesk, A.M., Tramontano, A., Levitt, M., Smith-Gill, S.J., Air, G., Sheriff, S., Padlan,
887 E.A., Davies, D., and Tulip, W.R., *et al.* (1989). Conformations of immunoglobulin hypervariable
888 regions. *NATURE* 342, 877-883.

889 Early, P., Huang, H., Davis, M., Calame, K., and Hood, L. (1980). An immunoglobulin heavy chain
890 variable region gene is generated from three segments of DNA: VH, D and JH. *CELL* 19, 981-992.

891 Faham, M., Zheng, J., Moorhead, M., Carlton, V.E., Stow, P., Coustan-Smith, E., Pui, C.H., and
892 Campana, D. (2012). Deep-sequencing approach for minimal residual disease detection in acute
893 lymphoblastic leukemia. *BLOOD* 120, 5173-5180.

894 Gawad, C., Pepin, F., Carlton, V.E.H., Klinger, M., Logan, A.C., Miklos, D.B., Faham, M., Dahl, G.,
895 and Lacayo, N. (2012). Massive evolution of the immunoglobulin heavy chain locus in children with
896 B precursor acute lymphoblastic leukemia. *BLOOD* 120, 4407-4417.

897 Glanville, J., Kuo, T.C., von Budingen, H.C., Guey, L., Berka, J., Sundar, P.D., Huerta, G., Mehta,
898 G.R., Oksenberg, J.R., and Hauser, S.L., *et al.* (2011). Naive antibody gene-segment frequencies are
899 heritable and unaltered by chronic lymphocyte ablation. *Proceedings of the National Academy of*
900 *Sciences* 108, 20066-20071.

901 Greiff, V., Miho, E., Menzel, U., and Reddy, S.T. (2015). Bioinformatic and Statistical Analysis of
902 Adaptive Immune Repertoires. *TRENDS IMMUNOL* 36, 738-749.

903 Greiff, V., Weber, C.R., Palme, J., Bodenhofer, U., Miho, E., Menzel, U., and Reddy, S.T. (2017).
904 Learning the High-Dimensional Immunogenomic Features That Predict Public and Private Antibody
905 Repertoires. *J IMMUNOL* 199, 2985-2997.

906 Hansen, T.O., Lange, A.B., and Barington, T. (2015). Sterile DJH rearrangements reveal that distance
907 between gene segments on the human Ig H chain locus influences their ability to rearrange. *J*
908 *IMMUNOL* 194, 973-982.

909 He, L., Sok, D., Azadnia, P., Hsueh, J., Landais, E., Simek, M., Koff, W.C., Poignard, P., Burton,
910 D.R., and Zhu, J. (2015). Toward a more accurate view of human B-cell repertoire by next-generation
911 sequencing, unbiased repertoire capture and single-molecule barcoding. *SCI REP-UK* 4.

912 Hoh, R.A., Joshi, S.A., Liu, Y., Wang, C., Roskin, K.M., Lee, J., Pham, T., Looney, T.J., Jackson,
913 K.J.L., and Dixit, V.P., *et al.* (2016). Single B-cell deconvolution of peanut-specific antibody
914 responses in allergic patients. *J ALLERGY CLIN IMMUN* 137, 157-167.

915 Hong, B., Wu, Y., Li, W., Wang, X., Wen, Y., Jiang, S., Dimitrov, D.S., and Ying, T. (2018).
916 In-Depth Analysis of Human Neonatal and Adult IgM Antibody Repertoires. *FRONT IMMUNOL* 9,
917 128.

918 Jackson, K.J., Kidd, M.J., Wang, Y., and Collins, A.M. (2013). The shape of the lymphocyte receptor
919 repertoire: lessons from the B cell receptor. *FRONT IMMUNOL* 4, 263.

920 Jackson, K.J., Liu, Y., Roskin, K.M., Glanville, J., Hoh, R.A., Seo, K., Marshall, E.L., Gurley, T.C.,
921 Moody, M.A., and Haynes, B.F., *et al.* (2014). Human responses to influenza vaccination show
922 seroconversion signatures and convergent antibody rearrangements. *CELL HOST MICROBE* 16,
923 105-114.

924 Jiang, N., He, J., Weinstein, J.A., Penland, L., Sasaki, S., He, X.S., Dekker, C.L., Zheng, N.Y., Huang,
925 M., and Sullivan, M., *et al.* (2013). Lineage structure of the human antibody repertoire in response to
926 influenza vaccination. *SCI TRANSL MED* 5, 119r-171r.

927 Joyce, M.G., Wheatley, A.K., Thomas, P.V., Chuang, G., Soto, C., Bailer, R.T., Druz, A., Georgiev,
928 I.S., Gillespie, R.A., and Kanekiyo, M., *et al.* (2016). Vaccine-Induced Antibodies that Neutralize
929 Group 1 and Group 2 Influenza A Viruses. *CELL* 166, 609-623.

930 Kidd, M.J., Jackson, K.J., Boyd, S.D., and Collins, A.M. (2016). DJ Pairing during VDJ
931 Recombination Shows Positional Biases That Vary among Individuals with Differing IGHD Locus
932 Immunogenotypes. *J IMMUNOL* 196, 1158-1164.

933 Kitaura, K., Yamashita, H., Ayabe, H., Shini, T., Matsutani, T., and Suzuki, R. (2017). Different
934 Somatic Hypermutation Levels among Antibody Subclasses Disclosed by a New Next-Generation
935 Sequencing-Based Antibody Repertoire Analysis. *FRONT IMMUNOL* 8.

936 Krebs, S.J., Kwon, Y.D., Schramm, C.A., Law, W.H., Donofrio, G., Zhou, K.H., Gift, S., Dussupt, V.,
937 Georgiev, I.S., and Schätzle, S., *et al.* (2019). Longitudinal Analysis Reveals Early Development of
938 Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual.
939 IMMUNITY 50, 677-691.

940 Kurtz, D.M., Green, M.R., Bratman, S.V., Scherer, F., Liu, C.L., Kunder, C.A., Takahashi, K., Glover,
941 C., Keane, C., and Kihira, S., *et al.* (2015). Noninvasive monitoring of diffuse large B-cell lymphoma
942 by immunoglobulin high-throughput sequencing. BLOOD 125, 3679-3687.

943 Larimore, K., McCormick, M.W., Robins, H.S., and Greenberg, P.D. (2012). Shaping of human
944 germline IgH repertoires revealed by deep sequencing. J IMMUNOL 189, 3221-3230.

945 Laserson, U., Vigneault, F., Gadala-Maria, D., Yaari, G., Uduman, M., Vander, H.J., Kelton, W., Taek,
946 J.S., Liu, Y., and Laserson, J., *et al.* (2014). High-resolution antibody dynamics of vaccine-induced
947 immune responses. Proc Natl Acad Sci U S A 111, 4928-4933.

948 Li, G.M., Chiu, C., Wrammert, J., McCausland, M., Andrews, S.F., Zheng, N.Y., Lee, J.H., Huang,
949 M., Qu, X., and Edupuganti, S., *et al.* (2012). Pandemic H1N1 influenza vaccine induces a recall
950 response in humans that favors broadly cross-reactive memory B cells. Proceedings of the National
951 Academy of Sciences 109, 9047-9052.

952 Liu, M., and Schatz, D.G. (2009). Balancing AID and DNA repair during somatic hypermutation.
953 TRENDS IMMUNOL 30, 173-181.

954 Liu, X., Zhang, W., Zeng, X., Zhang, R., Du, Y., Hong, X., Cao, H., Su, Z., Wang, C., and Wu, J., *et*
955 *al.* (2016). Systematic Comparative Evaluation of Methods for Investigating the TCR β Repertoire.
956 PLOS ONE 11, e152464.

957 Madi, A., Shifrut, E., Reich-Zeliger, S., Gal, H., Best, K., Ndifon, W., Chain, B., Cohen, I.R., and
958 Friedman, N. (2014). T-cell receptor repertoires share a restricted set of public and abundant CDR3
959 sequences that are associated with self-related immunity. GENOME RES 24, 1603-1612.

960 Maecker, H.T., Lindstrom, T.M., Robinson, W.H., Utz, P.J., Hale, M., Boyd, S.D., Shen-Orr, S.S., and
961 Fathman, C.G. (2012). New tools for classification and monitoring of autoimmune diseases. *NAT*
962 *REV RHEUMATOL* 8, 317-328.

963 Miho, E., Roskar, R., Greiff, V., and Reddy, S.T. (2019). Large-scale network analysis reveals the
964 sequence space architecture of antibody repertoires. *NAT COMMUN* 10, 1321.

965 Parameswaran, P., Liu, Y., Roskin, K.M., Jackson, K.K.L., Dixit, V.P., Lee, J., Artiles, K.L., Zompi,
966 S., Vargas, M.J., and Simen, B.B., *et al.* (2013). Convergent Antibody Signatures in Human Dengue.
967 *CELL HOST MICROBE* 13, 691-700.

968 Patil, S.U., Ogunniyi, A.O., Calatroni, A., Tadigotla, V.R., Ruitter, B., Ma, A., Moon, J., Love, J.C.,
969 and Shreffler, W.G. (2015). Peanut oral immunotherapy transiently expands circulating Ara h 2-
970 specific B cells with a homologous repertoire in unrelated subjects. *J ALLERGY CLIN IMMUN* 136,
971 125-134.

972 Pham, P., Bransteitter, R., Petruska, J., and Goodman, M.F. (2003). Processive AID-catalysed
973 cytosine deamination on single-stranded DNA simulates somatic hypermutation. *NATURE* 424,
974 103-107.

975 Pugh-Bernard, A.E., Silverman, G.J., Cappione, A.J., Villano, M.E., Ryan, D.H., Insel, R.A., and Sanz,
976 I. (2001). Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell
977 tolerance. *J CLIN INVEST* 108, 1061-1070.

978 Reddy, S.T., Ge, X., Miklos, A.E., Hughes, R.A., Kang, S.H., Hoi, K.H., Chrysostomou, C.,
979 Hunicke-Smith, S.P., Iverson, B.L., and Tucker, P.W., *et al.* (2010). Monoclonal antibodies isolated
980 without screening by analyzing the variable-gene repertoire of plasma cells. *NAT BIOTECHNOL* 28,
981 965-969.

982 Robins, H. (2013). Immunosequencing: applications of immune repertoire deep sequencing. *CURR*
983 *OPIN IMMUNOL* 25, 646-652.

984 Saada, R., Weinberger, M., Shahaf, G., and Mehr, R. (2007). Models for antigen receptor gene
985 rearrangement: CDR3 length. *IMMUNOL CELL BIOL* 85, 323-332.

- 986 Safonova, Y., and Pevzner, P.A. (2019). De novo Inference of Diversity Genes and Analysis of
987 Non-canonical V(DD)J Recombination in Immunoglobulins. *FRONT IMMUNOL* 10, 987.
- 988 Schramm, C.A., and Douek, D.C. (2018). Beyond Hot Spots: Biases in Antibody Somatic
989 Hypermutation and Implications for Vaccine Design. *FRONT IMMUNOL* 9, 1876.
- 990 Setliff, I., McDonnell, W.J., Raju, N., Bombardi, R.G., Murji, A.A., Scheepers, C., Ziki, R., Mynhardt,
991 C., Shepherd, B.E., and Mamchak, A.A., *et al.* (2018). Multi-Donor Longitudinal Antibody Repertoire
992 Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. *CELL HOST*
993 *MICROBE* 23, 845-854.
- 994 Shapiro, G.S., Aviszus, K., Ikle, D., and Wysocki, L.J. (1999). Predicting regional mutability in
995 antibody V genes based solely on di- and trinucleotide sequence composition. *J IMMUNOL* 163,
996 259-268.
- 997 Soto, C., Bombardi, R.G., Branchizio, A., Kose, N., Matta, P., Sevy, A.M., Sinkovits, R.S., Gilchuk,
998 P., Finn, J.A., and Crowe, J.E. (2019). High frequency of shared clonotypes in human B cell receptor
999 repertoires. *NATURE*.
- 1000 Souto-Carneiro, M.M., Sims, G.P., Girschik, H., Lee, J., and Lipsky, P.E. (2005). Developmental
1001 Changes in the Human Heavy Chain CDR3. *The Journal of Immunology* 175, 7425-7436.
- 1002 Stern, J.N.H., Yaari, G., Vander Heiden, J., Church, G., Donahue, W.F., Hintzen, R., Huttner, A.J.,
1003 Laman, J., Nagra, R.M., and Nylander, A., *et al.* (2014). B cells populating the multiple sclerosis brain
1004 mature in the draining cervical lymph nodes. *SCI TRANSL MED* 6, 107r-248r.
- 1005 Sui, J., Hwang, W.C., Perez, S., Wei, G., Aird, D., Chen, L., Santelli, E., Stec, B., Cadwell, G., and
1006 Ali, M., *et al.* (2009). Structural and functional bases for broad-spectrum neutralization of avian and
1007 human influenza A viruses. *NAT STRUCT MOL BIOL* 16, 265-273.
- 1008 Tipton, C.M., Fucile, C.F., Darce, J., Chida, A., Ichikawa, T., Gregoretti, I., Schieferl, S., Hom, J.,
1009 Jenks, S., and Feldman, R.J., *et al.* (2015). Diversity, cellular origin and autoreactivity of
1010 antibody-secreting cell population expansions in acute systemic lupus erythematosus. *NAT*
1011 *IMMUNOL* 16, 755-765.
- 1012 Tonegawa, S. (1983). Somatic generation of antibody diversity. *NATURE* 302, 575-581.

1013 Truck, J., Ramasamy, M.N., Galson, J.D., Rance, R., Parkhill, J., Lunter, G., Pollard, A.J., and Kelly,
1014 D.F. (2015). Identification of antigen-specific B cell receptor sequences using public repertoire
1015 analysis. *J IMMUNOL* *194*, 252-261.

1016 von Büdingen, H., Kuo, T.C., Sirota, M., van Belle, C.J., Apeltsin, L., Glanville, J., Cree, B.A.,
1017 Gourraud, P., Schwartzburg, A., and Huerta, G., *et al.* (2012). B cell exchange across the blood-brain
1018 barrier in multiple sclerosis. *The Journal of clinical investigation* *122*, 4533-4543.

1019 Wang, C., Liu, Y., Xu, L.T., Jackson, K.J., Roskin, K.M., Pham, T.D., Laserson, J., Marshall, E.L.,
1020 Seo, K., and Lee, J.Y., *et al.* (2014). Effects of aging, cytomegalovirus infection, and EBV infection
1021 on human B cell repertoires. *J IMMUNOL* *192*, 603-611.

1022 Weinstein, J.A., Jiang, N., White, R.A., Fisher, D.S., and Quake, S.R. (2009). High-Throughput
1023 Sequencing of the Zebrafish Antibody Repertoire. *SCIENCE* *324*, 807-810.

1024 Wu, X., Zhang, Z., Schramm, C.A., Joyce, M.G., Do Kwon, Y., Zhou, T., Sheng, Z., Zhang, B., O
1025 Dell, S., and McKee, K., *et al.* (2015). Maturation and Diversity of the VRC01-Antibody Lineage over
1026 15 Years of Chronic HIV-1 Infection. *CELL* *161*, 470-485.

1027 Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I., Wang, C., Chen, X., Longo, N.S., Louder, M., and
1028 McKee, K., *et al.* (2011a). Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by
1029 Structures and Deep Sequencing. *SCIENCE* *333*, 1593-1602.

1030 Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I., Wang, C., Chen, X., Longo, N.S., Louder, M., and
1031 McKee, K., *et al.* (2011b). Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by
1032 Structures and Deep Sequencing. *SCIENCE* *333*, 1593-1602.

1033 Wu, Y.B., James, L.K., Vander Heiden, J.A., Uduman, M., Durham, S.R., Kleinstein, S.H., Kipling,
1034 D., and Gould, H.J. (2014). Influence of seasonal exposure to grass pollen on local and peripheral
1035 blood IgE repertoires in patients with allergic rhinitis. *J ALLERGY CLIN IMMUN* *134*, 604-612.

1036 Zhu, J., Wu, X., Zhang, B., McKee, K., O'Dell, S., Soto, C., Zhou, T., Casazza, J.P., Mullikin, J.C.,
1037 and Kwong, P.D., *et al.* (2013a). De novo identification of VRC01 class HIV-1-neutralizing
1038 antibodies by next-generation sequencing of B-cell transcripts. *Proceedings of the National Academy*
1039 *of Sciences* *110*, E4088-E4097.

1040 Zhu, J., Wu, X., Zhang, B., McKee, K., O'Dell, S., Soto, C., Zhou, T., Casazza, J.P., Mullikin, J.C.,
1041 and Kwong, P.D., *et al.* (2013b). De novo identification of VRC01 class HIV-1-neutralizing
1042 antibodies by next-generation sequencing of B-cell transcripts. *Proceedings of the National Academy*
1043 *of Sciences* *110*, E4088-E4097.

1044

1045

1046 **DATA AVAILABILITY**

1047 In-house generated datasets are available at the NCBI Sequencing Read Archive
1048 (www.ncbi.nlm.nih.gov/sra) under BioProject number PRJNA564936. A table linking dataset
1049 accessions to their corresponding sample ids was provided in Table S9.

1050

Main figures

Figure 1




Figure 1 Overview of the enrolled datasets. (a) The number of samples in each enrolled project. The X axis shows NCBI SRA project IDs, and ZZHLAB indicates the antibody repertoires generated in our lab. The Y axis shows the log₁₀ transformed number of samples. The numbers of samples excluded by data size and experimental design are shown in red and grey, respectively. (b, c, d, e, f) show sample distribution based on (b) age; (c) sex; (d) PCR amplification strategy; (e) classification (healthy or diseased); and (f) various tissue or blood.




Figure 2 Germline gene usage and core V genes. (a) The heatmaps show the normalized usage of V (top panel), D (middle panel), and J (bottom panel) genes. Each column shows color-coded gene usage for a dataset. Each row shows usage pattern of a particular gene (IDs labeled on the left side) in different datasets. The bar graphs to the right of the heatmaps show the number of samples in which each gene was present. J genes were present in almost every sample. The bar graph on top of the V gene usage heatmap shows the number of V genes present in each sample. (b) and (c) The V genes were ordered based on their occurrences in 582 individuals from high (left) to low (right). The X-axis shows the number of high frequency V genes included. (b) The Y-axis shows the percent of total clones that were represented by the most frequent V genes shown on X-axis. The color shows the log₁₀ transformed number of samples each pixel represents. (c) The red line indicates the median fractions of total clones that were represented (left Y-axis) by the inclusion of top number of clones shown on X-axis. The blue line represents the slope of median clone fraction variation (on the red line) based on the adjacent 10 data points, 5 on the left and 5 on the right.




Figure 3 Gene usage patterns with regard to genetic background, age, and gender. (a) The Pearson's correlation (Pearson's r) distribution of the gene usage between 5,261 paired samples. The Pearson's r values were ordered from low to high. The red and light pink lines represent Pearson's r values calculated using all V genes and 53 core genes, respectively. The blue and green dots indicate the Pearson's r values between same and different cell types for monozygotic twins, respectively. (b) The relationship between core V genes and ages. The X-axis shows V gene ordered by frequency (Table 1). The Y-axis indicates the R^2 values calculated for a particular V gene at different ages (Supp. Fig. 6 and Materials and methods). (c), (d), and (e) show comparisons of core V (c), D (d), and J (e) genes between male and female. The red triangles indicate genes whose usage was significantly different between sexes.




Figure 4. Recombination and modification between V(D)J recombination. (a) Recombination count and frequency of different VD/DJ segments. The logarithm of the count is shown by the color of the points, and the frequency of recombination is shown by the size of the points. The line at the margin shows the number of each gene segment. V genes, core genes and non-core genes are marked. The arrow shows the direction in IGH locus. (b) Distribution of CDR3 length in all sample, clones with whole V, D, J assignment, and DD fusion. (c) Frequency of DD fusion in each isotype. The line plot shows the number of samples with at least 5,000 clones in each isotype. (d) D gene usage in DD fusion. (e) Frequency of DD fusion with different span; the span of adjacent D gene is 1. (f) The number of DD fusions in all clones, the x axis represents the D gene at the 5' end, and the y axis represents the D gene at the 3' end. The bar plot at the margin shows the number of each




Figure 5. Inter-sample abundance and gene usage of public clones. (a) The heatmap in the center indicates the abundance of public clones between samples. The top bar chart indicates the number of recovered total clones for each sample. The number of public clones between each pair of sample has been subjected to logarithmic transformation ($T = \log(1 + P_{ab})$). The number of public clones between samples within the same project has been set to 0 to remove chimera-related effects. Note that some samples from PRJNA260985 and PRJNA280743, were predicted to come from the same donors and the observed public clones between these samples was set to 0. (b) Linear model delineating the correlation between inter-sample public clone abundance and the product of their clone abundance. (c) Public clone size percentage as a function of donor sharing count.




Figure 6 | Somatic hypermutation patterns and influence factors. (a) The stacked column diagram shows the mutation percentage of motifs and composition of mutation targets. The X axis shows the different motifs in germline sequences. The Y axis shows the composition of the mutated nucleotide of this motif. The red-colored label represents hot-spot, the blue colored label represents cold-spot. The underlined letter represents the mutation site. (b) and (c) show the mutation rate among different functional alleles and families. (b) The combined heatmap shows the mutation rate among used functional alleles in selected IgG samples. Each column shows the position of completion of the V segment from FR1 to FR3. Each row shows the functional alleles occurred in datasets. The area chart represents the average mutation rate in every position. The bar graph left to the heatmap shows the family of occurred alleles which ordered by the number of clones who were shown in the right bar graph. The color of the heat map represents the mutation rate of every position from used functional alleles. (c) The X axis shows the position of the V segment from FR1 to FR3. The Y axis shows the average mutation rate from different families. The area chart shows the overall average mutation rate about used functional alleles. The red lines and blue dotted lines show the result of the mutation rate of every family based on consensus and weight matrix methods. (d) The combined heatmap shows the substitution among amino acid. Each column and each row represents an amino acid. The germline residue is located on the x axis, and the mutated amino acid is located on the Y axis. The line graphs represents the ability of each amino acid to be mutated and mutated. (e) The boxplot shows the mutation rate for different age groups across multiple functional region and whole region. The points on top of each boxplot indicates the outliers. (f) The scatter plot (orange for male and blue for female) shows the correlation between mutation rate and age. Two lines in the figure are the predicted linear regression model for male and female. R-squared value were marked on the top left in this figure.